Mazen Dimachkie
Mazen M. Dimachkie, MD, FAAN, FANA
Professor of Neurology & Director of Neuromuscular Division
Executive Vice Chairman & Vice Chairman for Research Program, Department of Neurology
University of Kansas Medical Center, Kansas City, Kansas, USA
Mazen M. Dimachkie, MD, FAAN, FANA, received his undergraduate and medical degrees from the American University of Beirut in Lebanon before completing an internship in Internal Medicine at Saint Agnes Hospital in Baltimore, Maryland. Dr. Dimachkie then completed a residency in Neurology at UT-Houston from July 1, 1990 to June 30, 1993 and fellowship in electromyography & Neuromuscular Disease from July 1, 1993 to June 30, 1994, both at The University of Texas Health Science Center at Houston (UT-Houston). He is ABPN board-certified in Neurology, Clinical Neurophysiology, and Neuromuscular Medicine and holds a UCNS certificate in Clinical Neuromuscular Pathology. He was elected as fellow member of the American Academy of Neurology and of the American Neurological Association. After being on faculty at the UT-Houston Neurology Department 1995-2007, he was recruited to lead the prolific neuromuscular Section and now Division at the University of Kansas Medical Center in Kansas City (KUMC). He is now Professor of Neurology, director of the Neuromuscular Division at the KUMC, director of the Neuromuscular Medicine Fellowship and Executive Vice Chairman & Vice Chairman for Research at the Neurology Department. As the director of KUMC Neuromuscular Research, he manages one of the busiest neuromuscular clinical trials units in North America. He leads and participates in a wide variety of federally-funded neuromuscular research studies and industry-sponsored studies, nationally and internationally. He has authored or co-authored more than 400 abstracts, articles, and book chapters. He is a frequently invited lecturer in the fields of myositis, myasthenia gravis, ALS, neuropathies and other neuromuscular topics. Dr. Dimachkie serves on the executive committee of the Muscle Study Group, and serves on the MSABs of the Myasthenia Gravis Foundation of America and The Myositis Association.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Dr. Dimachkie received research grants or contracts or educational grants from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Dr. Dimachkie received research grants or contracts or educational grants from MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics, The Myositis AssociationDate added:01/06/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Dr. Dimachkie received research grants or contracts or educational grants from UCB Biopharma / RaPharma, Viromed/Healixmith & TMA.Date added:01/06/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Dr. Dimachkie serves or recently served as a consultant for Amazentis, ArgenX, Catalyst, Cello, Covance/Labcorp, CSL-Behring, EcoR1, Janssen, Kezar, Momenta, NuFactor, Octapharma, RaPharma/UCB, Roivant Sciences Inc, RMS Medical, Sanofi GenzymeDate added:01/06/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Dr. Dimachkie serves or recently served as a consultant for Shire Takeda, Scholar Rock, Spark Therapeutics, Third Rock and UCB Biopharma.Date added:01/06/2022